Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year ...

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...

Moderna Inc. reported a wider-than-expected fourth-quarter loss on Wednesday, as the biotech company grapples with declining COVID-19 vaccine sales and ongoing restructuring costs. The vaccine maker ...